Working... Menu

Study of Coffee Mannooligosaccharides for Weight Management (MOS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00932750
Recruitment Status : Completed
First Posted : July 3, 2009
Last Update Posted : August 22, 2012
St. Luke's-Roosevelt Hospital Center
Information provided by:
Mondelēz International, Inc.

Brief Summary:
The goal of this study is to establish the role of coffee mannooligosaccharides (MOS), provided in a beverage format, on body weight regulation. Overweight and obese men and women will be randomized to one of 2 groups: placebo or MOS beverage. They will be required to consume 2 beverages/day for the duration of the 2 phases of the study. The MOS beverage will provide 2 g of MOS (total of 4 g/d). This dose level has been found to be well tolerated and safe. In the first phase, subjects will be counseled once monthly on a nutrition-related topic on an individual basis. They will be asked to maintain their regular eating and exercise habits for the duration of the 12 week period. An 8-week washout period will follow during which time they will not be required to consume the beverages. The second phase of the study will be a weight loss phase. For this phase, subjects will be re-randomized and may consume the alternate or the same beverage as the first phase, depending on the outcome of randomization. During this phase, they will undergo group counseling on a weekly basis. Counseling sessions will focus on weight loss and ways to achieve moderate weight loss of approximately 1-2 lbs/week. Measurements will be taken at the beginning and end of each phase. This study will allow us to determine whether MOS helps maintain body weight and prevent weight gain (first phase) and whether it helps to stimulate weight loss (second phase). The results will allow us to find ways in which overweight and obese individuals can incorporate beverages in their diets that will help promote weight loss.

Condition or disease Intervention/treatment Phase
Obesity Dietary Supplement: Coffee mannooligosaccharide Dietary Supplement: Coffee mannooligosaccharides Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 82 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Study Start Date : September 2006
Actual Primary Completion Date : November 2007
Actual Study Completion Date : November 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Body Weight

Arm Intervention/treatment
Placebo Comparator: MOS Weight maintenance Dietary Supplement: Coffee mannooligosaccharide
2 beverages daily providing either 4 g of coffee mannooligosaccharide or placebo.

Placebo Comparator: MOS weight loss Dietary Supplement: Coffee mannooligosaccharides
Subjects consume 2 beverages daily providing 4 g of coffee mannooligosaccharides or placebo

Primary Outcome Measures :
  1. Body Composition by Magnetic Resonance Imaging [ Time Frame: Baseline and Endpoint ]
  2. Blood pressure [ Time Frame: Weekly ]
  3. Body weight [ Time Frame: Weekly ]
  4. Waist circumference [ Time Frame: Weekly ]

Secondary Outcome Measures :
  1. Appetite/Satiety [ Time Frame: Weekly ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Body mass index 27-33 kg/m2
  • Stable body weight

Exclusion Criteria:

  • Body width > 46 cm
  • Medications known to affect body weight, lipids, blood pressure
  • Pregnant or lactating women
  • Less than 1 y post-partum

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00932750

Layout table for location information
United States, New York
St. Luke's/Roosevelt Hospital
New York, New York, United States, 10025
Sponsors and Collaborators
Mondelēz International, Inc.
St. Luke's-Roosevelt Hospital Center
Layout table for investigator information
Principal Investigator: Marie-Pierre St-Onge, Ph.D St. Luke's-Roosevelt Hospital Center

Layout table for additonal information
Responsible Party: Marie-Pierre St-Onge, Ph.D Research Associate, St. Luke's/Roosevelt Hospital Identifier: NCT00932750     History of Changes
Other Study ID Numbers: KF-MOS-01
First Posted: July 3, 2009    Key Record Dates
Last Update Posted: August 22, 2012
Last Verified: August 2012

Keywords provided by Mondelēz International, Inc.:
Body composition
Weight loss
Weight management